Investment firms Mubadala and Novo agreed to invest €250m in Evotec, a drug discovery alliance and development partnership company. "We welcome Mubadala to our group of strategic investors. There is no reason for us to slow down our mission in spite of the ongoing pandemic. We can and want to grow even faster and see a lot of positive momentum in our business strategy. We are delighted that Mubadala has chosen to invest in Evotec with a long-term view. Also, we are pleased to see that Novo Holdings continues to support our strategy. This investment allows us to further accelerate our strategy to create the world-leading “R&D Autobahn to Cures” from discovery to commercial manufacturing," Werner Lanthaler, Evotec CEO.